• Share on Facebook Share on LinkedIn Share on Twitter

Biostage claims success in animal esophagus regeneration study

March 13, 2018
Biostage CEO Jim McGorry.

Holliston biotech Biostage is eyeing formal clinical trials after results of a large animal study show the company's artificial throat implants can regenerate a functioning esophagus.

The study, published in Nature Scientific Reports, found the company's Cellspan esophageal implant was able to facilitate gradual structural regrowth of the esophageal tissue in a pig by using its own stem cells.

According to the study, the company's device, acting as a scaffold carrying a patient's stem cells, can be used as an alternative to the gastro-intestinal conduit currently used following the surgical damage of the esophagus.

The study is another in a string of good news for the company of late following a long period of financial hardships.

Last month, Biostage announced an autopsy showed a 75-year-old man's esophageal tube nearly fully regenerated thanks to the company's Cellspan implant.

The man, whose esophagus was damaged after a large tumor was removed from his chest, died of a stroke unrelated to the implant.

Biostage said last month the regenerative results were consistent with results seen in the company's large animal studies.

Thanks to a series of recent investments following delisting from NASDAQ and a 70 percent layoff, the company appears to be on sound financial footing for the time being.